Table 1 Patient demographics and baseline characteristics
Characteristic | Placebo (n = 169) | Upadacitinib 15 mg (n = 164) | Upadacitinib 30 mg (n = 165) |
|---|---|---|---|
Age (y), mean ± SD | 57.6 ± 11.4 | 56.3 ± 11.3 | 57.3 ± 11.6 |
Female, n (%) | 143 (84.6) | 137 (83.5) | 138 (83.6) |
Race, n (%) | |||
 White | 143 (84.6) | 142 (86.6) | 148 (89.7) |
 Black | 21 (12.4) | 17 (10.4) | 10 (6.1) |
 Asian | 5 (3.0) | 2 (1.2) | 2 (1.2) |
 Other | 0 (0) | 3 (1.8) | 5 (3.0) |
BMI (kg/m2), mean ± SD | 29.7 ± 7.4 | 31.2 ± 7.3 | 29.7 ± 6.2 |
Duration of RA (y), mean ± SD | 14.5 ± 9.2 | 12.4 ± 9.4 | 12.7 ± 9.7 |
Failed ≥ 1 anti-TNF, n (%) | 152 (89.9) | 146 (89.0) | 151 (92.1) |
Failed ≥ 1 bDMARD due to lack of efficacy, n (%) | 159 (94.1) | 146 (89.0) | 139 (84.8) |